Company Overview of ADC Therapeutics Sarl
ADC Therapeutics Sarl develops antibody drug conjugates (ADCs) and non-antibody drug conjugate products. The company is based in Lausanne, Switzerland. ADC Therapeutics Sarl operates as a subsidiary of Celtic Therapeutics Holdings L.P.
Key Executives for ADC Therapeutics Sarl
Co-Founder, Chairman and Managing General Partner of Auven Therapeutics
Senior Vice President of Research & Development
Chief Medical Officer and Head of Oncology Clinical Development
Compensation as of Fiscal Year 2015.
ADC Therapeutics Sarl Key Developments
ADC Therapeutics Sarl Announces Executive Changes
Jun 22 15
ADC Therapeutics Sarl announced the appointment of Dr. Chris Martin as its Chief Executive Officer. Dr. Martin was co-founder of Spirogen Ltd. and its Chief Executive Officer. Dr. Martin continued as CEO of Spirogen, and became both a member of Medimmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. Dr. Martin will continue to advise Medimmune as a consultant. Dr. Martin replaces Michael Forer who has served as CEO of the company since its formation. Mr. Forer is a Partner in the private equity firm Auven Therapeutics and was the lead investor on behalf of Auven for its majority investments in both Spirogen Ltd. and ADC Therapeutics. The company also announced that Mr. Forer becomes vice chairman of the company, and will continue to work with the company as executive vice president focused on its public markets capital strategy, business and finance activities.
ADC Therapeutics Submits its First IND for a Novel Antibody Drug Conjugate Against Lymphomas
Mar 16 15
ADC Therapeutics Sarl announced that it has filed an Investigational New Drug application (IND) with the US Food and Drug Administration as it moves its pipeline into clinical development. The IND is for a Phase I clinical trial for ADCT-301, a novel antibody drug conjugate targeting CD25, a cell-surface antigen, which is over-expressed in many patients with lymphomas. The Phase I clinical trial will commence at four leading oncology centres in the USA, and can expand into two centres in the United Kingdom. The initial up to 58 patient adaptive designed dose-escalation study, will evaluate the tolerability, safety, pharmacokinetics and antitumor activity of ADCT-301 in patients with relapsed or refractory Hodgkin's and Non-Hodgkin's lymphoma. Subject to study results, ADC Therapeutics intends to rapidly expand the numbers of patients in the trial and the participating clinical centres.
ADC Therapeutics Announces Board Appointment
Sep 30 14
ADC Therapeutics announced expansion of its team as the company's first ADCs enter clinical development. New team members include: Dr. Jay Feingold joins as Chief Medical Officer and Head of Oncology Clinical Development. Dr. Feingold has more than 25 years of industry, academic and medical experience and was most recently Vice President, US Medical Affairs and Chairman Global Medical Affairs Oversight Committee at Daiichi Sankyo. Prior to this, he served as Vice President of Clinical Development, Global Therapy Area Director, Oncology at Wyeth. Dr. Michael Mulkerrin joins as Head of CMC (Chemistry Manufacturing and Control). Dr. Mulkerrin has more than 20 years of industry experience in biologics manufacturing, most recently as Vice President, Process Development and Manufacturing at OncoMed and has had prior senior roles at Abgenix, Amgen and Genentech. Dr. Simon Chivers joins as Head of Toxicology. Dr. Chivers has more than 15 years of industry experience, most recently as Global Head Biologics Safety Assessment and Executive Director at Novartis and has had prior senior roles at AstraZeneca, Syngenta and Quintiles. Mr. Stéphane Henchoz joins as Director of Finance, bringing more than 20 years pharmaceutical industry finance experience, most recently working at Merck Serono.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|